Research To Practice | Oncology Videos Urothelial Bladder Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Urothelial Bladder Cancer
Featuring perspectives from Dr Matthew Galsky, Jonathan Rosenberg, and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath, including the following topics:
• Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky
o Introduction (00:00)
o Case: A man in his late 70s with superficial transitional cell carcinoma of the bladder after bacillus Calmette-Guérin with positive ureteral washing — Sunil Gandhi, MD (2:38)
o Cases: A man in his early 70s with high-grade papillary muscle-invasive bladder cancer with residual disease after neoadjuvant gemcitabine/cisplatin and cystectomy and a man in his early 80s with pT3N0 high-grade urothelial carcinoma after nephroureterectomy (GFR 40) — Ranju Gupta, MD and Swati Vishwanathan, MD (7:04)
o Faculty presentation: Dr Galsky (13:16)
• Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg
o Cases: A man in his mid 70s with metastatic urothelial carcinoma now on maintenance avelumab after gemcitabine/cisplatin and a man in his early 50s with a history of ulcerative colitis diagnosed with metastatic urothelial carcinoma, including brain involvement — Paul Markowski, MD and Gigi Chen, MD) (23:33)
o Case: A woman in her early 80s with unresectable localized urothelial carcinoma; PD-L1 CPS 5, TMB low — Spencer H Bachow, MD (30:54)
o Faculty presentation: Dr Rosenberg (36:21)
• Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke
o Case: A man in his mid 60s with metastatic bladder cancer and progressive disease on cisplatin/gemcitabine, now receiving sacituzumab govitecan — Priya Rudolph, MD, PhD (46:49)
o Case: A man in his mid 60s with de novo metastatic urothelial bladder cancer now receiving pembrolizumab after gemcitabine/carboplatin (rapid progressive disease, FGFR3 mutation) — Yanjun Ma, MD (51:42)
o Faculty presentation: Dr Siefker-Radtke (56:56)
• Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath
o Case: A man in his late 60s with metastatic urothelial carcinoma, PS 2 — Georges Azzi, MD (1:09:30)
o Cases: A man in his mid 70s with metastatic mixed-histology (urothelial, small cell) bladder cancer who receives pembrolizumab and remains in remission 5 years later and a man in his early 50s with metastatic small cell carcinoma of the bladder who receives cisplatin, etoposide and durvalumab followed by maintenance durvalumab, now NED — Victoria Giffi, MD and Laurie Matt-Amaral, MD, MPH (1:13:48)
o Faculty presentation: Dr Heath (1:19:43)